Shearman & Sterling advised the underwriters of HOOKIPA Pharma Inc.’s initial public offering of six million shares of common stock at a public offering price of $14.00 per share, resulting in gross proceeds to the Company of approximately $84 million. The shares began trading on the Nasdaq Global Select Market under the ticker symbol “HOOK” on April 18, 2019. 

BofA Merrill Lynch, SVB Leerink LLC and RBC Capital Markets, LLC acted as joint book-running managers for the offering and Kempen acted as co-manager. 

HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.

The Team